{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+Infusion+set&page=2", "query": { "intervention": "Standard Infusion set", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+Infusion+set&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-18T08:01:57.332Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02287428", "title": "Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Personalized NeoAntigen Peptides", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Poly-ICLC", "type": "BIOLOGICAL" } ], "intervention_types": [ "RADIATION", "BIOLOGICAL", "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2014-11", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-09-18T08:01:57.332Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02287428" }, { "nct_id": "NCT02940886", "title": "Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Iron Deficiency Anaemia", "Iron Deficiency Anemia" ], "interventions": [ { "name": "Iron isomaltoside/ferric derisomaltose", "type": "DRUG" }, { "name": "Iron sucrose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharmacosmos A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1512, "start_date": "2016-11-08", "completion_date": "2018-03-28", "has_results": true, "last_update_posted_date": "2020-10-06", "last_synced_at": "2026-09-18T08:01:57.332Z", "location_count": 114, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Guntersville, Alabama + 83 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Guntersville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02940886" }, { "nct_id": "NCT02903407", "title": "Pain, Agitation and Delirium (PAD) Protocol in the Duke CICU", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Deep Sedation", "Ventilators, Mechanical", "Critical Illness" ], "interventions": [ { "name": "Midazolam", "type": "DRUG" }, { "name": "Propofol", "type": "DRUG" }, { "name": "Dexmedetomidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2017-09-01", "completion_date": "2019-06-30", "has_results": true, "last_update_posted_date": "2020-07-13", "last_synced_at": "2026-09-18T08:01:57.332Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02903407" }, { "nct_id": "NCT02115126", "title": "Phase II Trial to Evaluate an EBV-derived Dendritic Cell Vaccine in Autologous Stem Cell Transplant", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hodgkin Lymphoma", "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "LMP2A-loaded conventional DC vaccine", "type": "BIOLOGICAL" }, { "name": "DUK-CPG-001", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "David Rizzieri, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2016-12", "completion_date": "2025-01", "has_results": false, "last_update_posted_date": "2016-11-01", "last_synced_at": "2026-09-18T08:01:57.332Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02115126" }, { "nct_id": "NCT00481832", "title": "Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "BCNU", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Antithymocyte globulin", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Autologous hematopoietic stem cell transplantation (auto-HSCT)", "type": "PROCEDURE" }, { "name": "Allogeneic hematopoietic stem cell transplantation (allo-HSCT)", "type": "PROCEDURE" }, { "name": "Total lymphoid irradiation", "type": "PROCEDURE" }, { "name": "CD34+ Cells", "type": "DRUG" }, { "name": "Solu-Medrol", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 50, "start_date": "2007-01", "completion_date": "2017-03-30", "has_results": true, "last_update_posted_date": "2018-02-14", "last_synced_at": "2026-09-18T08:01:57.332Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00481832" }, { "nct_id": "NCT03068819", "title": "Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "CIML NK Cell Infusion", "type": "DRUG" }, { "name": "CD3+ T Cell Product Infusion", "type": "PROCEDURE" }, { "name": "Leukapheresis", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2017-10-23", "completion_date": "2025-06-15", "has_results": true, "last_update_posted_date": "2026-04-24", "last_synced_at": "2026-09-18T08:01:57.332Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03068819" }, { "nct_id": "NCT03208478", "title": "Pain Control for Anterior Cruciate Ligament Reconstruction Patients With Adductor Canal or Femoral Perineural Infusions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pain, Postoperative", "Anterior Cruciate Ligament Injury" ], "interventions": [ { "name": "Adductor Canal perineural catheter placement", "type": "PROCEDURE" }, { "name": "Femoral Nerve perineural catheter placement", "type": "PROCEDURE" }, { "name": "Nimbus pump (Infutronix)", "type": "DEVICE" } ], "intervention_types": [ "PROCEDURE", "DEVICE" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2018-06-18", "completion_date": "2023-04-30", "has_results": false, "last_update_posted_date": "2023-07-24", "last_synced_at": "2026-09-18T08:01:57.332Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03208478" }, { "nct_id": "NCT07103486", "title": "A Study to Evaluate the Therapeutic Benefit of Tisagenlecleucel Compared to Existing Standard of Care in German Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Diffuse Large B-Cell Lymphoma" ], "interventions": [], "intervention_types": [], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 264, "start_date": "2021-04-01", "completion_date": "2023-01-31", "has_results": false, "last_update_posted_date": "2025-08-05", "last_synced_at": "2026-09-18T08:01:57.332Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT07103486" }, { "nct_id": "NCT03245892", "title": "A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "High Grade Serous Ovarian", "Fallopian Tube", "Primary Peritoneal Cancer" ], "interventions": [ { "name": "Carboplatin and Paclitaxel", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Cytoreductive surgery", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 27, "start_date": "2017-08-04", "completion_date": "2025-12-04", "has_results": false, "last_update_posted_date": "2025-12-17", "last_synced_at": "2026-09-18T08:01:57.332Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03245892" }, { "nct_id": "NCT04077463", "title": "A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Lazertinib", "type": "DRUG" }, { "name": "Amivantamab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 701, "start_date": "2019-09-04", "completion_date": "2028-03-27", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-09-18T08:01:57.332Z", "location_count": 18, "location_summary": "Los Angeles, California • Orange, California • San Francisco, California + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "West Hollywood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04077463" } ] }